Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended adjuvant imatinib after 3 years for high-risk GIST
NL-OMON59403Phase 3Active, not recruiting
- Sponsor
- Region Skåne
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Extended adjuvant imatinib with Observation after discontinuation (2 arms). Primary endpoint: Recurrence-free survival. Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON59403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59403.